Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

USP47 stabilizes YBX1 to promote the progression of acute myeloid leukemia

Oncogene volume 43, pages 539–542 (2024)Cite this article

Subjects

Dear editor,

Acute myeloid leukemia (AML) is a hematological malignancy characterized by the accumulation of immature myeloid cells caused by blocked differentiation, which has obvious molecular genetic characteristics [1]. FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) and mixed-lineage leukemia (MLL) gene rearrangement, two of the genomic abnormalities in AML, which are associated with frequent relapses and poor prognosis [2]. It is urgent to identify new molecular targets and treatment methods to improve the treatment of AML, especially in patients with poor prognosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: USP47 is highly expressed in AML and stabilizes YBX1 to maintain AML cell survival.
Fig. 2: USP47 promotes the progression of AML in mice.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.

    Article  PubMed  Google Scholar 

  2. DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401(2073):86.

    Google Scholar 

  3. Feng M, Xie X, Han G, Zhang T, Li Y, Li Y, et al. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021;138:71–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Perner F, Schnoeder TM, Xiong Y, Jayavelu AK, Mashamba N, Santamaria NT, et al. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia. 2022;36:426–37.

    Article  CAS  PubMed  Google Scholar 

  5. Xu JJ, Ji L, Liang YL, Wan Z, Zheng W, Song XM, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Tar. 2020;5:298.

    Article  CAS  Google Scholar 

  6. Lange SM, Armstrong LA, Kulathu Y. Deubiquitinases: From mechanisms to their inhibition by small molecules. Mol Cell. 2022;82:15–29.

    Article  CAS  PubMed  Google Scholar 

  7. Yu M, Fang ZX, Wang WW, Zhang Y, Bu ZL, Liu M, et al. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways. Acta Pharmacol Sin. 2021;42:604–12.

    Article  CAS  PubMed  Google Scholar 

  8. Lei H, Xu HZ, Shan HZ, Liu M, Lu Y, Fang ZX, et al. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia. Nat Commun. 2021;12:51.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cartel M, Mouchel PL, Gotanegre M, David L, Bertoli S, Mansat-De Mas V, et al. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy. Leukemia. 2021;35:417–32.

    Article  CAS  PubMed  Google Scholar 

  10. Lei H, Yang L, Wang Y, Zou Z, Liu M, Xu H, et al. JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression. Exp Hematol Oncol. 2022;11:42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from the National Natural Science Foundation of China (82170145, 81700475); CAMS Innovation Fund for Medical Sciences (CIFMS): 2019-I2M-5-051; Shanghai Municipal Commission of Health and Family Planning, NO. ZY (2021-2023)-0208; We thank the support from Shanghai Frontiers Science Center of Cellular Homeostasis and Human Diseases.

Author information

Authors and Affiliations

  1. Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Hu Lei, Hanzhang Xu, Li Yang, Yingying Wang, Youping Zhang & Yingli Wu

  2. Department of Pathophysiology, Research Unit of Stress and Cancer, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China

    Yingli Wu

  3. Shanghai Jiao Tong University, Research Units of Stress and Tumor (2019RU043), Chinese Academy of Medical Sciences, Sch Med, Shanghai, 200025, China

    Yingli Wu

Authors
  1. Hu Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanzhang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yingying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Youping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yingli Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The experiments were conceived and designed by HL and YW. The plasmids were constructed by HL and HX. HL performed animal experiments. The AML patient samples were collected by HL, LY, YZ and YW. The paper was written and revised by HL.

Corresponding authors

Correspondence to Hu Lei or Yingli Wu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lei, H., Xu, H., Yang, L. et al. USP47 stabilizes YBX1 to promote the progression of acute myeloid leukemia. Oncogene 43, 539–542 (2024). https://doi.org/10.1038/s41388-023-02921-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-023-02921-1

Search

Advanced search

Quick links